文献速递间质性肺疾病

抗纤维化治疗对IPF患者生存与肺功能的影响:INSIGHTS-IPF注册研究长期结果

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.
PubMed 文献 · Eur Respir J · 2020-08-13

该研究基于德国20家间质性肺病中心的588例IPF患者前瞻性队列数据,采用倾向性评分分析显示,接受抗纤维化治疗者1年生存率87% vs 未治疗者46%,2年生存率62% vs 21%,死亡风险降低37%(HR 0.63,95%CI 0.45-0.87,p=0.005),但FVC和DLCO下降速度在两组间无显著差异。

要点

  • 抗纤维化治疗与IPF患者生存率显著提高相关,死亡风险降低37%。
  • 接受与未接受抗纤维化治疗的患者FVC和DLCO下降速度无显著差异。
  • 临床实践中IPF患者尽管FVC和DLCO测量稳定,仍可能发生过早死亡。

核心结论

  • 抗纤维化治疗与IPF患者生存率显著提高相关,但肺功能参数变化在治疗与未治疗患者间相似。

研究设计与样本

  • 非干预性前瞻性队列研究,连续纳入德国20家间质性肺病专家中心的IPF患者,共588例适合分析。
  • 采用倾向性评分校正治疗与未治疗患者基线特征差异;数据质量通过自动合理性检查、现场监查和源数据验证保证。

主要发现

  • 平均±SD年龄69.8±9.1岁,男性占81.0%,自诊断以来平均±SD病程1.8±3.4年。
  • 基线FVC平均±SD为68.6±18.8%预计值,DLCO平均±SD为37.8±18.5%预计值。
  • 平均±SD随访1.2±0.7年期间,194例(33.0%)患者死亡。
  • 抗纤维化治疗组与未治疗组1年生存率分别为87%和46%,2年生存率分别为62%和21%。
  • 抗纤维化治疗患者死亡风险降低37%(HR 0.63,95%CI 0.45-0.87,p=0.005),多变量分析结果稳健且保持统计学显著。

临床怎么用

  • 临床实践中应认识到抗纤维化治疗可改善IPF患者生存,但肺功能稳定不代表死亡风险消失。
  • 对IPF患者即使FVC和DLCO测量稳定,仍需关注过早死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a paucity of observational data on antifibrotic therapy for idiopathic pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and without antifibrotic therapy under real-life conditions. METHODS: We analysed data from a non-interventional, prospective cohort study of consecutively enrolled IPF patients from 20 interstitial lung disease expert centres in Germany. Data quality was ensured by automated plausibility checks, on-site monitoring, and source data verification. Propensity scores were applied to account for known differences in baseline characteristics between patients with and without antifibrotic therapy. RESULTS: Among the 588 patients suitable for analysis, the mean±sd age was 69.8±9.1 years, and 81.0% were male. The mean±sd duration of disease since diagnosis was 1.8±3.4 years. The mean±sd value at baseline for forced vital capacity (FVC) and diffusion capacity (D LCO) were 68.6±18.8% predicted and 37.8±18.5% predicted, respectively. During a mean±sd follow-up of 1.2±0.7 years, 194 (33.0%) patients died. The 1-year and 2-year survival rates were 87% versus 46% and 62% versus 21%, respectively, for patients with versus without antifibrotic therapy. The risk of death was 37% lower in patients with antifibrotic therapy (hazard ratio 0.63, 95% CI 0.45; 0.87; p=0.005). The results were robust (and remained statistically significant) on multivariable analysis. Overall decline of FVC and D LCO was slow and did not differ significantly between patients with or without antifibrotic therapy. CONCLUSIONS: Survival was significantly higher in IPF patients with antifibrotic therapy, but the course of lung function parameters was similar in patients with and without antifibrotic therapy. This suggests that in clinical practice, premature mortality of IPF patients eventually occurs despite stable measurements for FVC and D LCO.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Behr J, Prasse A, Wirtz H, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020. PMID: 32381492. doi:10.1183/13993003.02279-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。